NEW YORK (GenomeWeb News) – ParagonDx said today that Iverson Genetic Diagnostics will use its pharmacogenomics test to determine warfarin sensitivity among patients taking the blood thinner.
 
IGD is a Seattle-based CLIA-certified lab that had been using a blood-based method for determining warfarin dosing, Research Triangle Park, NC-based ParagonDx said. Now, it will use a saliva-based test that incorporates ParagonDx’s technology and provides results the same day, as opposed to in two to three days with the blood-based test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.